Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says

Executive Summary

Advisory committee strongly favored approval of postpartum depression therapy, but many members suggest it should be administered in a facility with trained medical staff to avoid potential safety concerns.

Advertisement

Related Content

Janssen’s Esketamine: US FDA Panel To Weigh Efficacy, REMS Restrictions For Treatment-Resistant Depression
Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption
Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis
Sage May Be Forced To Simplify Brexanolone Dosing Regimen
US FDA's Internal Debate On Sage's Brexanolone Spills Into Open During Panel Review
Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel